Findings from the LIO-1 Trial in advanced metastatic tumors

In the phase 1b portion of the study, researchers investigated the recommended dose of lucitanib in combination with nivolumab in patients with advanced solid tumors. Complete and partial responses were demonstrated in 17 patients who received the combination, according to Hamilton. Stable disease was also reported in 10 patients.

These data were seen across several tumor types, including those that do not typically respond to immunotherapy. The combination is now being evaluated further in phase 2 of the trial.

For more information, watch the video and visit OncLive.​